Veracyte Inc Total Liabilities
Veracyte Inc total liabilities. Based on the latest financial reports, Veracyte Inc (VCYT) has total liabilities worth $97.96 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Veracyte Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Veracyte Inc (2011–2025)
Total liabilities of Veracyte Inc from 2011 to 2025. This chart illustrates how Veracyte Inc's total liabilities have evolved over time, based on quarterly financial data.
Veracyte Inc Competitors by Total Liabilities
The table below lists competitors of Veracyte Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Yangnong Chemical Co Ltd
SHG:600486
|
China | CN¥6.74 Billion |
|
National Beverage Corp
NASDAQ:FIZZ
|
USA | $201.41 Million |
|
Towne Bank
NASDAQ:TOWN
|
USA | $19.62 Billion |
|
Aneka Tambang Persero Tbk
JK:ANTM
|
Indonesia | Rp14.67 Trillion |
|
Cipher Mining Inc
NASDAQ:CIFR
|
USA | $6.91 Billion |
|
Marketech International Corp
TW:6196
|
Taiwan | NT$39.73 Billion |
|
Skeena Resources Ltd
TO:SKE
|
Canada | CA$951.63 Million |
|
Grupa KĘTY SA
WAR:KTY
|
Poland | zł2.72 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Veracyte Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VCYT total assets.
Liquidity & Leverage Metrics
Veracyte Inc Total Liabilities Ratios Explained
Veracyte Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Veracyte Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Veracyte Inc (2011–2025)
The table below shows the annual total liabilities of Veracyte Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $96.44 Million | -22.27% |
| 2024-12-31 | $124.07 Million | +75.23% |
| 2023-12-31 | $70.80 Million | -12.83% |
| 2022-12-31 | $81.22 Million | -11.05% |
| 2021-12-31 | $91.31 Million | +154.13% |
| 2020-12-31 | $35.93 Million | +0.49% |
| 2019-12-31 | $35.76 Million | -12.54% |
| 2018-12-31 | $40.88 Million | -1.35% |
| 2017-12-31 | $41.44 Million | -0.02% |
| 2016-12-31 | $41.45 Million | +72.48% |
| 2015-12-31 | $24.03 Million | +2.42% |
| 2014-12-31 | $23.46 Million | +1.20% |
| 2013-12-31 | $23.19 Million | +63.68% |
| 2012-12-31 | $14.17 Million | +637.43% |
| 2011-12-31 | $1.92 Million | -- |
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more